Abstract
Oxaliplatin (Eloxatin; Sanofi-Synthelabo) is the first platinum-based anticancer drug to be approved for the treatment of colorectal cancer, a major cause of cancer deaths worldwide. Following European approval in 1999, has approval of oxaliplatin by the US FDA in August 2002 set it on the road to becoming a blockbuster?
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Downregulation of KRAB zinc finger proteins in 5-fluorouracil resistant colorectal cancer cells
BMC Cancer Open Access 04 April 2022
-
Effectiveness of nivolumab affected by prior cetuximab use and neck dissection in Japanese patients with recurrent or metastatic head and neck cancer: results from a retrospective observational study in a real-world setting
International Journal of Clinical Oncology Open Access 08 April 2021
-
The hybrid models, containing hydrolytic and electron-driven processes, in theoretical study of oxaliplatin biotransformation
Journal of Molecular Modeling Open Access 26 September 2020
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Parkin, D. M. et al. Cancer burden in the year 2000. The global picture. Eur. J. Cancer 37, S4–S66 (2001).
Longley, D. B. et al. 5-fluorouracil: mechanisms of action and clinical strategies. Nature Rev. Cancer 3, 330–338 (2003).
Jamieson, E. R. & Lippard, S. J. Structure, recognition, and processing of cisplatin–DNA adducts. Chem. Rev. 99, 2467–2498 (1999).
Di Francesco, A. M. et al. Cellular and molecular aspects of drugs of the future: oxaliplatin. Cell. Mol. Life Sci. 59, 1914–1927 (2002).
Raymond, E. et al. Oxaliplatin: mechanism of action and antineoplastic activity. Semin. Oncol. 25, 4–12 (1998).
Rixe, O. et al. Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen Panel. Biochem. Pharmacol. 52, 1855–1865 (1996).
FDA Drug Approvals List [online], (cited 28 November 2003), <http://www.fda.gov/cder/foi/label/2002/21492lbl.pdf> (2002).
Goldberg, R. M. et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J. Clin. Oncol. Dec 9 2003 (doi: 10.1200/JCO.2004.09.046)
De Gramont, A. et al. Oxaliplatin/5-FU/LV in adjuvant colon cancer: results of the international randomized mosaic trial. Proc. Am. Soc. Clin. Oncol. 22, 253 (2003).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Graham, J., Muhsin, M. & Kirkpatrick, P. Oxaliplatin. Nat Rev Drug Discov 3, 11–12 (2004). https://doi.org/10.1038/nrd1287
Issue Date:
DOI: https://doi.org/10.1038/nrd1287
This article is cited by
-
Chemotactic nanomotor for multimodal combined therapy of glioblastoma
Science China Chemistry (2024)
-
Downregulation of KRAB zinc finger proteins in 5-fluorouracil resistant colorectal cancer cells
BMC Cancer (2022)
-
Nanoparticle-mediated convection-enhanced delivery of a DNA intercalator to gliomas circumvents temozolomide resistance
Nature Biomedical Engineering (2021)
-
Effectiveness of nivolumab affected by prior cetuximab use and neck dissection in Japanese patients with recurrent or metastatic head and neck cancer: results from a retrospective observational study in a real-world setting
International Journal of Clinical Oncology (2021)
-
6-Shogaol enhances the anticancer effect of 5-fluorouracil, oxaliplatin, and irinotecan via increase of apoptosis and autophagy in colon cancer cells in hypoxic/aglycemic conditions
BMC Complementary Medicine and Therapies (2020)
